Screener
Regenxbio RGNX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Proceeds from issuance of royalty bond and warrants, net of transaction costs | — | 144,526 |
| Repayments under royalty monetization liabilities, net of interest | (15,181) | (10,854) |
| Net cash provided by financing activities | 3,932 | 133,438 |
| Net increase in cash and cash equivalents and restricted cash | 2,021 | 22,032 |
| Cash and cash equivalents and restricted cash | ||
| Beginning of period | 36,496 | 59,556 |
| End of period | $38,517 | $81,588 |
| Supplemental disclosures of non-cash investing and financing information |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's net change in cash?
- Regenxbio (RGNX) reported net change in cash of $21.26M in Q2 2026.
- What is the long-term trend for Regenxbio's net change in cash?
- Over 2 years (2021 to 2023), Regenxbio's net change in cash has grown at a 188.8% compound annual growth rate (CAGR), from $7.48M to -$62.43M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Regenxbio's net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude